Leaving Community
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Blog
dkNET community events and announcements in February, 2018
Dear dkNET Community,
dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.
dkNET Updates:
- New resources added to dkNET
Preventing Early Renal Loss in Diabetes (PERL) (RRID:SCR_015862) is a clinical trial for people with type 1 diabetes who have early signs of kidney problems. Its goal is to test a new way to reduce loss of kidney function using a safe and inexpensive medicine.
National Gene Vector Laboratories (RRID:SCR_015944) was established as a cooperative national effort to produce and distribute vectors for human gene transfer studies.
scater (RRID:SCR_015954) is a software toolkit for doing various analyses of single-cell RNA-seq gene expression data, with a focus on quality control. This package facilitates pre-processing, quality control, normalization and visualization of scRNA-seq data.
Events in February, 2018
Feb. 1-2, 2018
Individualizing Treatment for Urinary Incontinence - Evolving Research Questions into Research Plans
The goal of this meeting is to build on the ideas generated by the March 2017 meeting to develop fundable, interdisciplinary, investigator-initiated research proposals that will lead to better outcomes for currently available treatments by individualizing them to each patient, considering characteristics across the spectrum from biology to the social determinants of health. Adopting this broader framework for research will require engaging researchers from scientific fields beyond urology. Registration deadline: Jan. 26, 2018.
Location: Bethesda, MD, USA
More information: https://www.niddk.nih.gov/news/events-calendar/Pages/individualizing-treatment-urinary-incontinence-evolving-research-questions-research-plans-2017.aspx
Feb. 2, 2018
IIDP Human Islet Workshop: Counting, Culturing, and Other Helpful Hints
This workshop is designed to introduce investigators to the IIDP resource and to provide new researchers with some of the basic techniques needed when handling human islets.More information: https://iidp.coh.org/onlineapp/workshop/info.aspx
Feb. 4-8, 2018
Keystone Symposium: Frontiers in Islet Biology and Diabetes (B3)
Location: Keystone, CO, USA
More information: http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1568
Feb. 16, 2018
NIF Webinar: Cellosaurus Presented by Dr. Amos Bairoch
Biography: Amos Bairoch is a Swiss bioinformatician and Professor of Bioinformatics at the Department of Human Protein Sciences of the University of Geneva where he leads the CALIPHO group at the Swiss Institute of Bioinformatics (SIB) combining bioinformatics, biocuration, and experimental efforts to functionally characterize human proteins. Until June 2009, Amos headed the Swiss-Prot group which develops the UniProtKB/Swiss-Prot knowledgebase which he created in 1986 as well as the PROSITE and ENZYME databases. He was also co-responsible for the development of ExPASy, the world's first website dedicated to protein molecular biology. Currently his main activities are focused on the development of neXtProt, a web knowledge platform on human proteins and of the Cellosaurus. Amos Bairoch has been awarded several distinctions, among which the European Latsis Prize, the Otto Naegeli Prize and the HUPO Distinguished Achievement Award. He is an ISCB Fellow.
Synopsis: The Cellosaurus (https://web.expasy.org/cellosaurus/) is a knowledge resource on cell lines. The aim of this webinar is to describe the content of the Cellosaurus but also to discuss some issues mundane to cell lines especially misidentification/contamination, naming problems as well the lack of standardization of the information reported by cell line collections/companies. We will also describe our collaboration with ICLAC (http://iclac.org/) and our involvement in the Resource Identification Initiative (https://www.force11.org/group/resource-identification-initiative).
More information: https://uchealth.zoom.us/j/597433523
Feb. 17, 2018
BPS18 62th Biophysical Society Annual Meeting
As science becomes increasingly interdisciplinary, the Biophysical Society Annual Meeting continues its long-held reputation for bringing together leading scientists from the all over the world who work at the interface of the life, physical, and computational sciences. The dynamic five-day Meeting provides attendees with opportunities to share their latest unpublished findings and learn the newest emerging techniques and applications.
Location: San Francisco, CA, USA
More information: http://www.biophysics.org/2018meeting/GeneralInfo/Overview/tabid/7118/Default.aspx
Feb. 20-23, 2018
nPOD Annual Meeting 2018
The Network for Pancreatic Organ Donors with Diabetes (nPOD) is proud to host its 10th Annual Meeting at The Diplomat Beach Resort, February 20-23, 2018. Over the past eleven years, JDRF nPOD has made remarkable strides in terms of meeting its organizational goals. Key amongst these include seeing its investigators make discoveries that help answer the question of, “What causes type 1 diabetes?” We anticipate the 2018 meeting will continue to foster meaningful collaborations towards that goal through directed topic presentations and discussions.
Location: Hollywood, FL, USA
More information: https://www.jdrfnpod.org/category/news-events/
Feb. 25 - Mar. 1, 2018
Keystone Symposia: Uncomplicating Diabetes: Reducing the Burden of Diabetes Related End-Organ Injury (J7)
Location: Santa Fe, NM, USA
More information: http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1526
Feb. 26, 2018
Workshop Registration Deadline: Autophagy as a Common Pathway in Diseases 2018
Autophagy is a carefully choreographed cellular response to stress and environmental changes. The cell creates specific structures to facilitate targeted degradation of components in lysosomes, thereby recycling materials and adjusting cellular contents to suit the new environmental conditions. In recent years, researchers have implicated disruptions of autophagy in numerous diseases within the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) mission. These include cystinosis, the systemic amyloidoses, tuberous sclerosis, acute tubule necrosis, and ciliopathies. The purpose of this conference is to bring together autophagy researchers and those working on NIDDK-relevant disease biology to explore potential common mechanisms and to discuss potential therapeutic development strategies. If successful, this meeting will promote new collaborations and avenues of investigation that identify novel diagnostic tools and new interventions and improve clinical outcomes for diseases relevant to the NIDDK’s mission.
Location: Bethesda, MD, USA
More information: https://www.niddk.nih.gov/news/meetings-workshops/2018/autophagy-common-pathway-diseases
Feb. 28, 2018
Workshop Application deadline: 2018 Data Science Innovation Lab: Mathematical Challenges of Single Cell Dynamics
The BD2K Training Coordinating Center is organizing an Innovation Lab to foster the development of new interdisciplinary teams via a facilitated and mentored format to tackle the technology and mathematical challenges which are creating roadblocks in utilization of single cell multimodal data acquisition, compatibility, and its wider integration. Date: June 25-29, 2018.
Location: Riverhouse on the Deschutes
More information: https://bigdatau.ini.usc.edu/innovationlab2018
Funding opportunities information and deadlines in February, 2018
Feb. 1, 2018
Funding Opportunity Application Due Date: Environmental Health Sciences Research Center (EHSRC) Pilot Grant Program
The EHSRC Pilot Grant Program seeks innovative, environmental health-related research proposals from University of Iowa researchers eligible to apply for K or R01 grants from NIH. Proposals for laboratory and/or field research will be accepted. Areas of EHSRC interest for funding include, but are not limited to, the following: Studies of susceptibility to environmentally induced disease (gene/environment interactions), Nanotoxicology, Environmental risk factors for disease, Fundamental biology with environmental relevance, Environmental and mammalian toxicology, Occupational and environmental medicine, Assessment of exposures to environmental agents, and Environmental remediation and control.All University of Iowa researchers eligible for apply for K or R01 grants from NIH are invited to apply. This specifically includes Post-doctoral Fellows, Post-doctoral Scholars, Faculty (all ranks) and Research Scientists, Research Engineers, Associate Research Scientists, Associate Research Engineers, Other categories of individuals; students and staff may not be investigators but may be designated to receive salary support and should be listed in the budget. Eligibility: Post-doctoral Fellows, Post-doctoral Scholars, Faculty (all ranks) and Research Scientists, Research Engineers, Associate Research Scientists, Associate Research Engineers at the University of Iowa.
More information: https://cph.uiowa.edu/ehsrc/pilot-grants/overview.html
Feb. 1, 2018
Funding Opportunity Application Due Date: Northwestern University Feinberg School Of Medicine Cognitive Neurology And Alzheimer’s Disease Center Pilot Project Grant Proposal Opportunity
The proposed research project must be relevant to clinical or basic research on Alzheimer’s disease, other dementias or cognitive aging. Frontotemporal degeneration, primary progressive aphasia and unusually successful brain aging are additional areas of emphasis. Proposals that are based on human subjects of the Northwestern Alzheimer’s Disease Center or its tissue resources (DNA, fixed brain, frozen brain) will be given priority. Eligibility: The principal investigator must hold a faculty appointment, or be a postdoctoral fellow at North- western University.
More information: http://www.brain.northwestern.edu/research/for-researchers/pilotproject.html
Funding Opportunity Application Due Date: Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases
The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research must reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere.
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-011.html
Feb. 2, 2018
Funding opportunity application due date: Lymphatics in Health and Disease in the Digestive System
The purpose of this FOA is to invite applications that investigate aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in this system and its organs, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. However, studies with the major focus on immune mechanisms, role of lymphatics in cancer metastasis and study of lymphatic vessels in organs other than those from the digestive system will not be considered responsive.Feb. 2, 2018
Funding Opportunity Application Due Date: University Of Pennsylvania Institute On Aging And Alzheimer’s Disease Core Center Pilot Study
The University of Pennsylvania Institute on Aging (IOA) and Alzheimer’s Disease Core Center (ADCC) will fund up to six (6) one-year multidisciplinary pilot grants in the 2015-2016 academic year to support biomedical, epidemiological, behavioral or health services research, as well as basic science, clinical or psychosocial research. Two of the pilots, funded by Penn’s ADCC, will focus on Alzheimer’s disease (AD) and related neurodegenerative disorders as well as healthy brain aging. The remaining pilots, supported by funding from the Perelman School of Medicine at Penn (PSOM) to the IOA, will focus on aging and aging-related diseases as well as healthy aging. Eligibility: The Principal Investigator (PI) for each of these pilots must be a member of the University of Pennsylvania fulltime faculty from any of its 12 schools.Feb. 5, 2018
Funding Opportunity Standard Application Due Date: Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the NIDDK (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) seeks to accelerate the pace and expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within NIDDK's mission by leveraging ongoing large, multi-center clinical research studies through ancillary studies. This Funding Opportunity Announcement (FOA) invites research project applications to conduct ancillary studies to major ongoing clinical research studies, including clinical trials and prospective observational studies. Applications submitted to this FOA must propose to collect new information and/or biological samples directly from participants of the ongoing parent study, and must address new research questions that are beyond those specified in the approved protocol of the parent study and are within the scientific mission of the NIDDK. This FOA cannot be used to extend the duration of the parent study.Feb. 5, 2018
Funding Opportunity Standard Application Due Date: Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under this FOA are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors.Feb. 5, 2018
Funding Opportunity Standard Application Due Date: Natural History of Disorders Identifiable by Screening of Newborns (R01 Clinical Trial Optional)
This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field.In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.Feb. 5, 2018
Funding Opportunity Standard Application Due Date: Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to promote application of nutrigenetics and/or nutrigenomics approaches to nutrition research through collaborative interaction among nutrition researchers and experts in omics technologies.Feb. 5, 2018
Funding Opportunity Standard Application Due Date: Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations which propose to characterize or identify factors in early childhood (birth-24 months) that may increase or mitigate risk for obesity and/or excessive weight gain and/or to fill methodological research gaps relevant to the understanding of risk for development of obesity in children. Studies should propose research in children from birth to 24 months, although any proposed follow-up assessments, if applicable, may continue past this period. Studies may also assess factors relevant to families and/or caregivers of children from birth to 24 months. Applications should seek to fill unique research needs and involve expertise across disciplines as appropriate for the proposed research question.
Feb. 5, 2018
Funding Opportunity Application Due Date: Metabolic Contributions to the Neurocognitive Complications of Diabetes: Ancillary Studies (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites applications for human studies to elucidate the etiology and pathogenesis of the increased risk for neurocognitive impairment associated with type 2 diabetes.Feb. 12, 2018
Letter of Intent Due Date: Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK
The overarching goal of this Funding Opportunity Announcement (FOA) is to translate basic science research into knowledge and tools that can be utilized to provide strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, hematology, and specific aspects of cystic fibrosis. Additional information concerning programmatic areas at NIDDK is available at: www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx.
Its objective is to stimulate research and technology development to promote the early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called "therapeutic leads") such as small molecules or non-viral biologics (e.g. antibodies, cell-based therapies, engineered tissue constructs, probiotic or commensal microbes) that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in either the target, small molecule, or non-viral biologic itself, or in the approaches used to pursue further therapeutic lead validation, and that this is articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, or generating lists of putative new targets.
At the end of the project period, a successful project will have provided a significant contribution to the data supporting the validity of modulating a target’s activity for safe, efficacious treatment of a disease using a small molecule or non-viral biologic approach.Feb. 13, 2018
Funding Opportunity Application Due Date: George M. O'Brien Urology Cooperative Research Centers Program (U54Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for the George M. O’Brien Urology Cooperative Research Centers Program. This program will provide a coordinated platform for multidisciplinary interactions between basic and clinical scientists with the overall goal of understanding the etiology and development of benign urologic diseases and disorders, and providing a collaborative venue to design better treatments, diagnostics, and prevention strategies for these disease conditions within the NIDDK mission interests. This program will also serve as a national resource to the larger urological research community and provide educational enrichment opportunities to scientists electing to pursue research in benign urology. Accordingly, applications are sought from individuals willing to cooperate with the NIDDK under a cooperative centers program. The funded Centers will work with the NIDDK in facilitating research collaborations and interactions within and among centers and with the larger research community to accomplish the overall goal of improving treatment of urologic disorders through enhanced communication and research excellence.Feb. 13, 2018
Letter of Intent Due Date: Studies of HIV in Digestive Diseases Limited to Gastrointestinal Mucosal Immunology and Liver Diseases (R01 Clinical Trial Optional)
The goal of this FOA is to support innovative, basic and translational research in two areas, gastrointestinal (GI) mucosal immunology and liver disease. The emphasis for GI mucosal immunology is on elucidation of mechanisms whereby innate and adaptive immunity in the GI tract interacts with HIV infection in the presence or absence of antiretroviral therapy (ART) and contributes to HIV infection, persistence, disruption of GI homeostasis, and pathogenesis. The emphasis for liver disease is on pathophysiologic mechanisms of injury to the liver and the biliary system during HIV infection and epidemiological studies of liver diseases and disorders in HIV patients.Feb. 16, 2018
Diabetes Innovation Challenge Submission Deadline
T1D Exchange and lead sponsors JDRF and The Helmsley Charitable Trust are pleased to announce the 2018 Diabetes Innovation Challenge. 2018 Diabetes Innovation Challenge is offering $250,000 in cash and in-kind Prizes to diabetes innovations!Feb. 20, 2018
Letter of Intent Due Date: Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 - Clinical Trial Not Allowed
NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing. Eventually, collections of iPSCs that capture the heterogeneity of T2D could be used to conduct "clinical trials in a dish", to discover biomarkers of response and to develop personalized treatments. An essential feature of this program will be a multidisciplinary approach that brings together basic science experts and physician scientists in stem cell biology, bioengineering, computational biology, pharmacology, liver biology, islet biology, adipose biology, metabolism and diabetes.Feb. 23, 2018
Funding Opportunity Application Due Date: The Johns Hopkins University - University Of Maryland (JHU-UMD) Diabetes Research Center (DRC) Pilot And Feasibility Program
The Pilot and Feasibility (P and F) Program, directed by Dr. Sally Radovick, of the JHU-UMD Diabetes Research Center (DRC) is seeking applications to support new initiatives in diabetes-related biomedical, epidemiological or behavioral research. The JHU-UMD DRC is an NIH-funded joint-venture between the Johns Hopkins University, University of Maryland and Howard University School of Medicine. It is composed of Cores that are designed to support research in diabetes and related endocrine and metabolic diseases. The JHU-UMD DRC is one of seven national centers. Application deadline will be the last Friday of the following February.More information: https://www.hopkinsmedicine.org/diabetes-research-center/pilot-feasibility/index.html
Feb. 26, 2018
Funding Opportunity Application Due Date: UCSF Diabetes Research Center (DRC) Pilot And Feasibility Awards
The DRC Pilot & Feasibility Program is funded through a Center grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to stimulate new directions in diabetes research regardless of a laboratory's traditional focus. Pilot funding of up to $50,000 per application is available for a duration of 12 months from the time of award. Enhanced Pilot & Feasibility Awards of up to $100,000 for each of one or two years will be considered for highly exceptional proposals in clinical and translational research studies, innovative partnerships between clinical and basic research or in development of broadly useful and innovative technologies. Projects initially selected for Enhanced Pilot & Feasibility awards only will be offered after approval by NIDDK officials. Enhanced Pilot & Feasibility award holders also will be eligible to apply competitively for further bridge funding.The reviewers will examine the proposals for innovative research that will generate, within one year, seed data sufficient for future NIH grant applications in any aspect of clinical or basic research directly related to type 1 or type 2 diabetes. One year projects that create new knowledge or capabilities that can be used widely throughout the local and extramural diabetes research community also may be submitted in response to this RFA. Collaborative efforts with UCSF faculty currently engaged in diabetes-related research may better enable the successful completion of the approved research programs. Eligibility: UCSF faculty.Feb. 28, 2018
Funding opportunity application due date: Developmental Centers for Interdisciplinary Research in Benign Urology (P20 - Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for the Developmental Centers for Interdisciplinary Research in Benign Urology Program (P20). Among the goals of this Program is to further advance research in benign urology by building research teams and facilitating resources generation and sharing. The research teams should be composed of individuals with complementary expertise who propose to either develop innovative resources (Resource Development Projects) or a new research project (Scientific Research Projects) that utilize integrative approaches to address questions relevant to benign urological diseases or disorders. Patient-centered research is encouraged. Resources developed by the Resource Development Projects will be shared upon validation while resources developed within the Scientific Research Projects will be shared at the end or termination of the award, as appropriate and consistent with the program goal of further advancing research. Each Developmental Center is centered on a single Project and must contain an Administrative Core and an Educational Enrichment Program. As part of the efforts of the Division of Kidney, Urologic and Hematologic Diseases (DKUH) to expand and enhance benign urology research, the Developmental Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe) Career Development Program.
About
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant 2U24DK097771-09.
Contact Us
Email: info_at_ dknet.org
